Each type of porphyria involves a genetic defect in a heme biosynthesis pathway enzyme. They are classified as the following: acute hepatic porphyria (AHP)—which may present as a sudden neurovisceral acute attack—or photocutaneous porphyria.1-3
Using Major Clinical Manifestations for Classification of 8 Types of Porphyria3,4
ADP=aminolevulinic acid dehydratase-deficiency porphyria; AIP=acute intermittent porphyria; ALA=aminolevulinic acid; CEP=congenital erythropoietic porphyria; EPP=erythropoietic protoporphyria; HCP=hereditary coproporphyria; PBG=porphobilinogen; PCT=porphyria cutanea tarda; VP=variegate porphyria; XLDPP=X-linked dominant protoporphyria.
This site is dedicated to discussing AHP. For information about all types of porphyria, including both AHP and photocutaneous porphyria, visit the American Porphyria Foundation website.
Causes of AHP
The types of porphyria are genetic metabolic disorders of the heme biosynthesis pathway. AHP, a subset of porphyria, often presents as a sudden acute attack requiring hospitalization and is triggered by excess ALA and PBG.2-5
Watch this Mechanism of Disease video to take a deeper look at the pathogenesis, signs and symptoms, and common methods used to inform a diagnosis of AHP:
AHP is caused by enzymatic defects that result in accumulation in the liver of toxic intermediates—aminolevulinic acid (ALA) and porphobilinogen (PBG). Upregulation of ALAS1 (aminolevulinate acid synthase 1) is a central pathophysiologic mechanism underlying AHP, and leads to this toxic accumulation. ALA and PBG then enter the circulatory system and are thought to cause neurologic lesions leading to dysfunction across the autonomic, central, and peripheral nervous systems. Dysfunction in these systems can cause patients to have severe, diffuse abdominal pain plus one or more of the following symptoms: anxiety, confusion, nausea, vomiting, limb weakness and pain. This can potentially result in irreversible neuropathies and long-term disease complications such as kidney disease and hepatocellular carcinoma. Elevated PBG is important as a highly specific diagnostic marker. ALA is believed to be the primary toxic intermediate responsible for causing acute attacks, ongoing symptoms between attacks, and prolonged or potentially permanent neuropathy in AHP. Acute attacks generally last 3 to 7 days, but the recovery period can be long and extend into residual chronic symptoms.1-9
AHP Consists of 4 TYPES
There are 4 types of AHP, which stem from different enzyme deficiencies in the heme biosynthesis pathway in the liver. About 80% of cases are acute intermittent porphyria (AIP), followed by variegate porphyria (VP), hereditary coproporphyria (HCP), and the extremely rare ALA dehydratase-deficiency porphyria (ADP). The prevalence of AIP may be under-reported due to estimates based on patients with symptomatic disease only, rather than an enzyme mutation.2,4,5,10
Epidemiology of AHP
In the US, the overall prevalence of people diagnosed with symptomatic AHP is approximately 10 per 1 million people. It affects people of all races. The majority of cases occur in women of reproductive age, with most attacks occurring between the ages of 15 and 45. Importantly, the risk of long-term disease consequences, such as porphyria-related kidney disease or hepatocellular carcinoma, remains after menopause. Some patients experience debilitating and potentially life-threatening attacks.2-4,10-16
References: 1. Puy H, Gouya L, Deybach JC. Lancet. 2010; 375:924-937. 2. Anderson KE, Bloomer JR, Bonkovsky HL, et al. Ann lntem Med. 2005;142(6):439-450. 3. Bissell DM, Anderson KE, Bonkovsky HL. N Engl J Med. 2017;377(9):862-872. 4. Bissell DM, Wang B. J Clin Transl Hepatol. 2015;3(1):17-26. 5. Simon A, Pompilus F, Querbes W, et al. Patient. 2018;11(5):527-537. 6. Lin CS, Lee MJ, Park SB, Kiernan MC. Clin Neurophysiol. 2011;122:2336-2344. 7. Szlendak U, Bykowska K, Lipniacka A. Adv Clin Exp Med. 2016;25(2):361-368. 8. Pischik E, Kauppinen R. Appl Clin Genet. 2015;8:201-214. 9. Balwani M, Wang B, Anderson KE, et al; for the Porphyrias Consortium of Rare Diseases Clinical Research Network. Hepatology. 2017;66(4):1314-1322. 10. Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. J Inherit Metab Dis. 2013; 36:849-857. 11. Ramanujam VM, Anderson KE. Curr Protoc Hum Genet. 2016; 86:17.20.1-17.20.26. 12. Bonkovsky HL, Maddukuri VC, Yazici C, et al. Am J Med. 2014;127(12):1233-1241. 13. Ko JJ, Murray S, Merkel M, et al. Poster presented at: American College of Gastroenterology Annual Scientific Meeting; October 5-10, 2018; Philadelphia, PA. 14. Pallet N, Mami l, Schmitt C, et al. Kidney Internal. 2015;88:386‐395. 15. Baravelli CM, Sandberg S, Aarsand AK, Nilsen RM, Tollanes MC. J Int Med. 2017;282(3):229-240. 16. Ventura P, Cappellini MD, Biolcati G, Guida CC, Rocchi E; Gruppo Italiano Porfiria (GrlP). Eur J Intern Med. 25(6):497-505. 17. Gouya L, Bloomer JR, Balwani M, et al. Presented at: The International Liver Congress; April 14, 2018; Paris, France. 18. Anderson KE. Mol Genet Metab. 2019;128(3):219-227. 19. Sardh E, Harper P, Balwani M, et al. N Engl J Med. 2019;380(6):549-558.